Niagen Bioscience Sells ChromaDex Reference Standards to LGC for $XXM
Event summary
- Niagen Bioscience sold its ChromaDex Reference Standards business to LGC on February 24, 2026, in an all-cash transaction.
- The divestiture aims to streamline operations and focus on NAD+ science and commercial growth.
- LGC Standards, a division of LGC Group, expands its portfolio with ChromaDex standards to support pharmaceutical customers and laboratories.
- Niagen Bioscience CEO Rob Fried emphasized the transaction aligns with the company's strategy to exit non-core activities.
The big picture
Niagen Bioscience's sale of its ChromaDex Reference Standards business to LGC marks a strategic pivot towards core NAD+ science and commercial growth. This move aligns with broader industry trends of biotech companies streamlining operations to focus on high-impact opportunities. The transaction underscores Niagen Bioscience's commitment to advancing healthy aging through precision science and innovative NAD+-boosting solutions.
What we're watching
- Strategic Focus
- How Niagen Bioscience's divestiture will impact its ability to advance NAD+ science and commercial growth.
- Market Positioning
- Whether the sale of non-core assets will enhance Niagen Bioscience's competitive edge in the longevity industry.
- Execution Risk
- The pace at which Niagen Bioscience can integrate the proceeds from the sale into its core NAD+ business.
Related topics